{"component": "definition", "props": {"groups": [{"snippet": "means current Good Manufacturing Practices as specified in the United States Code of Federal Regulations, ICH Guideline Q7A, or equivalent laws, rules, or regulations of an applicable Regulatory Authority at the time of manufacture.", "samples": [{"hash": "kVLrCP9pW8a", "uri": "/contracts/kVLrCP9pW8a#cgmp", "label": "License and Collaboration Agreement (Adicet Bio, Inc.)", "score": 36.5975341797, "published": true}, {"hash": "f6iCUW6ahoB", "uri": "/contracts/f6iCUW6ahoB#cgmp", "label": "Collaboration, License and Development Agreement (Ionis Pharmaceuticals Inc)", "score": 36.5756340027, "published": true}, {"hash": "7hMGGkEsXt0", "uri": "/contracts/7hMGGkEsXt0#cgmp", "label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "score": 36.5756340027, "published": true}], "size": 150, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [6, 42]}, {"key": "as-specified", "type": "clause", "offset": [43, 55]}, {"key": "united-states-code-of-federal-regulations", "type": "definition", "offset": [63, 104]}, {"key": "or-equivalent", "type": "definition", "offset": [125, 138]}, {"key": "applicable-regulatory-authority", "type": "definition", "offset": [173, 204]}, {"key": "at-the-time", "type": "definition", "offset": [205, 216]}], "hash": "e7e7894303ccb16f9f58e1f1b84e1909", "id": 1}, {"snippet": "means current Good Manufacturing Practice as set forth in the United States Federal Food, Drug, and Cosmetic Act, as amended, and includes all rules and regulations promulgated by the FDA thereunder.", "samples": [{"hash": "j0MNDsJaw3z", "uri": "https://www.fdanews.com/ext/resources/files/04/04-21-14-CaseDocuments.pdf", "label": "Agreement", "score": 11.1409988403, "published": false}, {"hash": "8Edsyvahc38", "uri": "https://www.ftc.gov/system/files/documents/cases/ani_novitium_do_4_2021.10.25.pdf", "label": "www.ftc.gov", "score": 11.0150585175, "published": false}, {"hash": "dQlcJTZkGJJ", "uri": "https://www.ftc.gov/system/files/documents/cases/2110101c4754aninovitiumdecisionandorder.pdf", "label": "www.ftc.gov", "score": 10.9288158417, "published": false}], "size": 101, "snippet_links": [{"key": "current-good-manufacturing-practice", "type": "definition", "offset": [6, 41]}, {"key": "united-states-federal", "type": "definition", "offset": [62, 83]}, {"key": "as-amended", "type": "definition", "offset": [114, 124]}, {"key": "rules-and-regulations", "type": "clause", "offset": [143, 164]}, {"key": "the-fda", "type": "clause", "offset": [180, 187]}], "hash": "9f5bfe1b3ae043ae78fb6a85b86990fb", "id": 2}, {"snippet": "means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities that may be in effect from time to time and are applicable to the Manufacture of the Compounds.", "samples": [{"hash": "3HeYv3V7YgP", "uri": "/contracts/3HeYv3V7YgP#cgmp", "label": "Clinical Trial Collaboration and Supply Agreement (Olema Pharmaceuticals, Inc.)", "score": 36.2087593079, "published": true}, {"hash": "hJIBX9XNxli", "uri": "/contracts/hJIBX9XNxli#cgmp", "label": "Clinical Trial Collaboration and Supply Agreement (IDEAYA Biosciences, Inc.)", "score": 33.8514709473, "published": true}, {"hash": "7VJsF5PxJwC", "uri": "/contracts/7VJsF5PxJwC#cgmp", "label": "Clinical Trial Collaboration and Supply Agreement (Context Therapeutics Inc.)", "score": 33.6078033447, "published": true}], "size": 85, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [10, 46]}, {"key": "officially-published", "type": "definition", "offset": [47, 67]}, {"key": "applicable-regulatory-authorities", "type": "definition", "offset": [106, 139]}, {"key": "in-effect", "type": "definition", "offset": [152, 161]}, {"key": "from-time-to-time", "type": "clause", "offset": [162, 179]}, {"key": "applicable-to", "type": "definition", "offset": [188, 201]}], "hash": "434a98e59baeb51ce5b6e9b28b210d8f", "id": 3}, {"snippet": "means current Good Manufacturing Practices as defined in regulations promulgated by the FDA under the Act and corresponding regulations in the other countries of the Territory.", "samples": [{"hash": "lt6meVU6DUN", "uri": "/contracts/lt6meVU6DUN#cgmp", "label": "Development, License and Supply Agreement (Eurand N.V.)", "score": 21.0, "published": true}, {"hash": "lkTvUBzJ23D", "uri": "/contracts/lkTvUBzJ23D#cgmp", "label": "Development, License and Supply Agreement (Reliant Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "hIdQqDQ2bul", "uri": "/contracts/hIdQqDQ2bul#cgmp", "label": "Exclusive Development/License/Supply Agreement (Axcan Intermediate Holdings Inc.)", "score": 21.0, "published": true}], "size": 70, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [6, 42]}, {"key": "the-fda", "type": "clause", "offset": [84, 91]}, {"key": "under-the-act", "type": "clause", "offset": [92, 105]}, {"key": "other-countries", "type": "definition", "offset": [143, 158]}, {"key": "the-territory", "type": "clause", "offset": [162, 175]}], "hash": "fcd1b46c08fa22c9974a82350f5bc337", "id": 4}, {"snippet": "means the then-current good manufacturing practices as required by the FDA under provisions of 21 C.F.R. Parts 210 and 211 and all applicable FDA rules, regulations, orders, and guidances, and the requirements with respect to current good manufacturing practices prescribed by the European Community under provisions of \u201cThe Rules Governing Medicinal Products in the European Community, Volume 4, Good Manufacturing Practices, Annex 13, Manufacture of Investigational Medicinal Products, July 2003,\u201d or as otherwise required by Applicable Law.", "samples": [{"hash": "2sDyzVnaJQG", "uri": "/contracts/2sDyzVnaJQG#cgmp", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.2902107239, "published": true}, {"hash": "ePTlG1r6D3N", "uri": "/contracts/ePTlG1r6D3N#cgmp", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.0985641479, "published": true}, {"hash": "42jemUzzxtM", "uri": "/contracts/42jemUzzxtM#cgmp", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 36.0444908142, "published": true}], "size": 63, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [15, 51]}, {"key": "as-required-by", "type": "clause", "offset": [52, 66]}, {"key": "the-fda", "type": "clause", "offset": [67, 74]}, {"key": "provisions-of", "type": "clause", "offset": [81, 94]}, {"key": "fda-rules", "type": "definition", "offset": [142, 151]}, {"key": "the-requirements", "type": "clause", "offset": [193, 209]}, {"key": "with-respect-to", "type": "clause", "offset": [210, 225]}, {"key": "european-community", "type": "definition", "offset": [281, 299]}, {"key": "rules-governing", "type": "clause", "offset": [325, 340]}, {"key": "annex-13", "type": "definition", "offset": [427, 435]}, {"key": "investigational-medicinal-products", "type": "clause", "offset": [452, 486]}, {"key": "july-2003", "type": "clause", "offset": [488, 497]}, {"key": "applicable-law", "type": "clause", "offset": [528, 542]}], "hash": "76e78fd6226559a93175a522ea185049", "id": 5}, {"snippet": "means all applicable current Good Manufacturing Practices including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, (b) European Directive 2003/94/EC and Eudralex 4, (c) the principles detailed in the ICH Q7 guidelines, and (d) the equivalent Applicable Laws in any relevant country or region, each as may be amended and applicable from time to time.", "samples": [{"hash": "3r4GDzN5ZMy", "uri": "/contracts/3r4GDzN5ZMy#cgmp", "label": "License Agreement (Vor Biopharma Inc.)", "score": 34.6112251282, "published": true}, {"hash": "5iUa7zBke6a", "uri": "/contracts/5iUa7zBke6a#cgmp", "label": "License Agreement (Turning Point Therapeutics, Inc.)", "score": 33.5995903015, "published": true}, {"hash": "ea5MYOCTSDq", "uri": "/contracts/ea5MYOCTSDq#cgmp", "label": "License Agreement (Zai Lab LTD)", "score": 32.3538665771, "published": true}], "size": 62, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [21, 57]}, {"key": "the-principles", "type": "clause", "offset": [88, 102]}, {"key": "the-us", "type": "clause", "offset": [115, 122]}, {"key": "directive-2003-94", "type": "definition", "offset": [222, 239]}, {"key": "applicable-laws", "type": "clause", "offset": [336, 351]}, {"key": "relevant-country", "type": "definition", "offset": [359, 375]}, {"key": "from-time-to-time", "type": "clause", "offset": [425, 442]}], "hash": "3ac6fde7181642096e386389e2d1e0b6", "id": 6}, {"snippet": "means current Good Manufacturing Practice as defined in Parts 210 and 211 of Title 21 of the U.S. Code of Federal Regulations, as may be amended from time to time, or any successor thereto.", "samples": [{"hash": "5cQqF2meUdM", "uri": "/contracts/5cQqF2meUdM#cgmp", "label": "Development, Promotion, Distribution and Supply Agreement", "score": 21.0, "published": true}, {"hash": "2BxzEKwSlF8", "uri": "/contracts/2BxzEKwSlF8#cgmp", "label": "License Agreement (Durect Corp)", "score": 21.0, "published": true}, {"hash": "kLe4ss1C1UY", "uri": "/contracts/kLe4ss1C1UY#cgmp", "label": "Supply Agreement (Dusa Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 55, "snippet_links": [{"key": "current-good-manufacturing-practice", "type": "definition", "offset": [6, 41]}, {"key": "the-us", "type": "clause", "offset": [89, 96]}, {"key": "code-of-federal-regulations", "type": "definition", "offset": [98, 125]}, {"key": "from-time-to-time", "type": "clause", "offset": [145, 162]}], "hash": "3ff93077b10302f0e157d202a35a49d3", "id": 7}, {"snippet": "means the then current good manufacturing practices and regulatory requirements for or concerning manufacturing practices for pharmaceutical or biological products (and components thereof) that are promulgated or endorsed for the United States by the FDA (including through 21 CFR Parts 210 and 211) and for outside the United States by comparable Governmental Authorities.", "samples": [{"hash": "jOs0p3pq4IO", "uri": "/contracts/jOs0p3pq4IO#cgmp", "label": "Credit Agreement (Esperion Therapeutics, Inc.)", "score": 37.2491455078, "published": true}, {"hash": "z3t1GLlbO9", "uri": "/contracts/z3t1GLlbO9#cgmp", "label": "Credit Agreement (Esperion Therapeutics, Inc.)", "score": 35.9486656189, "published": true}, {"hash": "iyleNoaNwW7", "uri": "/contracts/iyleNoaNwW7#cgmp", "label": "Credit Agreement (Calliditas Therapeutics AB)", "score": 35.3107452393, "published": true}], "size": 52, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [15, 51]}, {"key": "requirements-for", "type": "clause", "offset": [67, 83]}, {"key": "biological-products", "type": "definition", "offset": [144, 163]}, {"key": "for-the-united-states", "type": "clause", "offset": [222, 243]}, {"key": "the-fda", "type": "clause", "offset": [247, 254]}, {"key": "outside-the-united-states", "type": "clause", "offset": [308, 333]}, {"key": "governmental-authorities", "type": "definition", "offset": [348, 372]}], "hash": "38ed2fd10869caf80a1fbb464c6ddedd", "id": 8}, {"snippet": "means current Good Manufacturing Practices (a) as promulgated under 21 C.F.R. Parts 210 and 211, as the same may be amended or re-enacted from time to time and (b) as required by law in countries other than the United States where pharmaceutical product Manufacturing is conducted.", "samples": [{"hash": "kgrtKIHuXHF", "uri": "/contracts/kgrtKIHuXHF#cgmp", "label": "Sublicense Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.6310749054, "published": true}, {"hash": "kEqha794Kyb", "uri": "/contracts/kEqha794Kyb#cgmp", "label": "Sublicense Agreement (Tg Therapeutics, Inc.)", "score": 27.6036968231, "published": true}, {"hash": "1VuycUuOlGa", "uri": "/contracts/1VuycUuOlGa#cgmp", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.5242977142, "published": true}], "size": 52, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [6, 42]}, {"key": "from-time-to-time", "type": "clause", "offset": [138, 155]}, {"key": "as-required-by-law", "type": "clause", "offset": [164, 182]}, {"key": "the-united-states", "type": "definition", "offset": [207, 224]}, {"key": "product-manufacturing", "type": "clause", "offset": [246, 267]}], "hash": "71e02bafd4aa67c0799817209199c45b", "id": 9}, {"snippet": "means current good manufacturing practices applicable to the Manufacture of Product promulgated by any Authority.", "samples": [{"hash": "1oxQOtvD3kl", "uri": "/contracts/1oxQOtvD3kl#cgmp", "label": "Development and Manufacturing Services Agreement", "score": 31.3408622742, "published": true}, {"hash": "krSAGz7LIAb", "uri": "/contracts/krSAGz7LIAb#cgmp", "label": "Development and Manufacturing Services Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 26.8535251617, "published": true}, {"hash": "cJqIZhUDlPw", "uri": "/contracts/cJqIZhUDlPw#cgmp", "label": "Development and Manufacturing Services Agreement (Radius Health, Inc.)", "score": 26.1854896545, "published": true}], "size": 46, "snippet_links": [{"key": "current-good-manufacturing-practices", "type": "clause", "offset": [6, 42]}, {"key": "applicable-to", "type": "definition", "offset": [43, 56]}, {"key": "manufacture-of-product", "type": "clause", "offset": [61, 83]}], "hash": "b1166a70885e949445069f51d42de830", "id": 10}], "next_curs": "ClESS2oVc35sYXdpbnNpZGVyY29udHJhY3Rzci0LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiINY2dtcCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means current Good Manufacturing Practices as specified in the United States Code of Federal Regulations, ICH Guideline Q7A, or equivalent laws, rules, or regulations of an applicable Regulatory Authority at the time of manufacture.", "title": "cGMP", "size": 3350, "id": "cgmp", "examples": ["In the event of a conflict between this Agreement and the Quality Agreement with respect to quality-related activities, including compliance with <strong>CGMP</strong>, the provisions of the Quality Agreement shall govern.", "Prior to the first Processing of Product hereunder subject to <strong>CGMP</strong>, the parties shall negotiate in good faith and enter into a quality agreement (as revised from the to time, the \u201cQuality Agreement\u201d)."], "related": [["cgmps", "cGMPs", "<strong>cGMPs</strong>"], ["gmp", "GMP", "GMP"], ["good-manufacturing-practices", "Good Manufacturing Practices", "Good Manufacturing Practices"], ["good-manufacturing-practice", "Good Manufacturing Practice", "Good Manufacturing Practice"], ["manufacturing-process", "Manufacturing Process", "Manufacturing Process"]], "related_snippets": [], "updated": "2026-05-16T04:22:31+00:00"}, "json": true, "cursor": ""}}